Business Context and Reporting Period
Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) filed this Form 8-K on April 8, 2014, to report the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics
- Shares Offered: 1,600,000 shares of common stock.
- Public Offering Price: $64.00 per share.
- Underwriter Purchase Price: $60.16 per share.
- Expected Net Proceeds: Approximately $96.0 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 240,000 additional shares.
Material Changes
This filing represents a significant capital raise event. The company entered into an underwriting agreement with Jefferies LLC, Barclays Capital Inc., and Merrill Lynch, Pierce, Fenner & Smith Incorporated. The transaction is expected to close on or about April 14, 2014. The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a current report focused on a specific transaction rather than a periodic financial statement.
Outlook and Management Commentary
The company utilized an automatically effective shelf registration statement on Form S-3 filed on April 7, 2014. A press release announcing the pricing of the offering was issued on April 8, 2014. The filing does not contain specific forward-looking guidance on revenue or earnings, nor does it detail specific risks beyond the standard incorporation of the underwriting agreement by reference.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 14, 2014).
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 240,000 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific conditions precedent or indemnification clauses.
- Check subsequent filings to confirm the actual net proceeds received versus the estimated $96.0 million.